Recro Pharma

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. Our lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo controlled trial demonstrating pain relief. We have studied various dosage forms of Dex in eight completed clinical studies, two of which were placebo controlled trials that demonstrated meaningful pain relief. As our product candidates are not opioid based drugs, we expect to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect. We are ready to begin a Phase IIb trial with Dex in patients experiencing post-operative pain. We believe Dex will become an alternative pain medication to opioids for the more than 50 million surgical procedures that require post-operative pain medication. If approved, Dex would also be the first and only approved post-operative pain drug in its class of drugs.
Type
Public
HQ
Malvern, US
Employees
186 (est)
Recro Pharma is headquartered in Malvern, US

Recro Pharma Locations

Malvern, US

Recro Pharma Metrics

Recro Pharma Summary

Market capitalization

$80.4 M

Closing share price

$6.99
Recro Pharma's latest market capitalization is $80.4 M.

Recro Pharma Market Value History

Recro Pharma News

Recro Pharma Company Life

You may also be interested in